Physician profile
William A Greisner
NPI 1720095334
$39,339.31
in general payments reported to CMS, 2019-2025
43 companies · $14K in 2025
The $14K reported for 2025 was more than what 90% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,384 · 2020: $1,860 · 2021: $2,403 · 2022: $2,755 · 2023: $5,531 · 2024: $8,001 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Food and Beverage: $11K · Travel and Lodging: $1,123 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,000 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,136.74 |
| Food and Beverage | $10,577.77 |
| Travel and Lodging | $1,122.88 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,000.00 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $8,511.48 | 2019-2025 | Xolair |
| Lilly USA, LLC | $5,383.16 | 2025 | Ebglyss |
| Kaleo, INC. | $3,721.81 | 2019-2025 | Auvi-Q |
| Optinose US, INC. | $3,055.62 | 2019-2025 | |
| Genzyme Corporation | $3,029.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $2,283.25 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Novartis Pharmaceuticals Corporation | $2,084.77 | 2019-2023 | |
| Glaxosmithkline, LLC. | $1,669.02 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,464.33 | 2019-2025 | Dupixent |
| Csl Behring | $1,182.55 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Pfizer INC. | $1,093.16 | 2019-2025 | |
| Amgen INC. | $976.85 | 2020-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $673.04 | 2021-2023 | Orladeyo |
| Blueprint Medicines Corporation | $631.31 | 2022-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $588.25 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $485.71 | 2019-2024 | Grastek, Ragwitek, Odactra |
| Adma Biomanufacturing LLC | $427.14 | 2021-2025 | |
| Grifols USA, LLC | $295.92 | 2019-2025 | Prolastin-C Liquid, Xembify |
| Ars Pharmaceuticals Operations, INC. | $204.95 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $176.80 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $176.80 | 2020-2023 | Airduo Digihaler |
| Genentech, INC. | $162.06 | 2023-2025 | Xolair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.88 | 2020-2021 | |
| Leo Pharma INC. | $111.44 | 2024-2025 | Adbry |
| Circassia INC. | $96.74 | 2019 | |
| Pharming Healthcare, INC. | $94.86 | 2021-2025 | Ruconest |
| Incyte Corporation | $94.83 | 2022-2023 | Opzelura |
| Octapharma USA, INC. | $75.08 | 2022-2025 | Panzyga |
| Shire North American Group INC | $59.21 | 2019 | |
| Covis Pharma Gmbh | $56.90 | 2020-2022 | |
| Cycle Pharmaceuticals INC | $55.31 | 2025 | Sajazir |
| Greer Laboratories, INC. | $50.05 | 2019 | |
| Abbvie INC. | $45.86 | 2023 | |
| Azurity Pharmaceuticals, INC. | $37.93 | 2025 | Alvesco |
| Dermavant Sciences, INC. | $32.91 | 2023 | Vtama |
| Organon LLC | $32.54 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $31.97 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Ionis Pharmaceuticals, INC. | $17.50 | 2025 | Dawnzera |
| Bio Products Laboratory USA, INC. | $15.51 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Greisner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.